ArticleWorld journal of gastroenterology2012
Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Diagnostic value of circulating miRNA-122 for hepatitis B virus and/or hepatitis C virus-associated chronic viral hepatitis.Bioscience reports · 2019Pooled it
- Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury.British journal of clinical pharmacology · 2023Trial
- Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery.PloS one · 2025Article
- Article
- Liquid Liver Biopsy for Disease Diagnosis and Prognosis.Journal of clinical and translational hepatology · 2023Review
- Therapeutic interventions of acute and chronic liver disorders: A comprehensive review.World journal of hepatology · 2023Review
- Plasma Exosome-Derived microRNAs Profiles in Patients with Serofast Status: A Cross-Sectional Study.International journal of general medicine · 2023Article
- Advances of microRNAs in regulating mitochondrial function: new potential application in NAFLD treatment.Molecular biology reports · 2022Review
- Factors influencing circulating microRNAs as biomarkers for liver diseases.Molecular biology reports · 2022Review
- Serum Expression Level of MicroRNA-122 and Its Significance in Patients with Hepatitis B Virus Infection.Journal of healthcare engineering · 2022Article
- MicroRNA in dried blood spots from patients with Aagenaes syndrome and evaluation of pre-analytical and analytical factors.Pediatric research · 2021Article
- Correlation of serum microRNA-122 level with the levels of Alanine aminotransferase and HBV-DNA in Chronic HBV-infected patients.Medical journal of the Islamic Republic of Iran · 2021Article
- Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases.Gastroenterology and hepatology from bed to bench · 2021Review
- Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling.International journal of molecular sciences · 2020Review
- A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.Microorganisms · 2020Review
- MicroRNA-744/transforming growth factor β1 relationship regulates liver cirrhosis.Hepatology international · 2019Article
- Expression and significance of urinary microRNA in patients with chronic hepatitis B.Medicine · 2019Article
- MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis.Oncotarget · 2018Article
- A miRNA Host Response Signature Accurately Discriminates Acute Respiratory Infection Etiologies.Frontiers in microbiology · 2018Article
- Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate whether circulating microRNAs (miRNAs) can serve as molecular markers to predict liver injury resulted from chronic hepatitis B (CHB).
methodsThe profiles of serum miRNA expression were first generated with serum samples collected from 10 patients with CHB and 10 healthy donors (Ctrls) by microarray analysis. The levels of several miRNAs were further quantitated by real-time reverse transcription polymerase chain reaction with serum samples from another 24 CHB patients and 24 Ctrls. Serum samples of 20 patients with nonalcohlic steatohepatitis (NASH) were also included for comparison. The comparison in the levels of miRNAs between groups (CHB, NASH and Ctrl) was analyzed with Mann-Whitney U-test. The correlation between miRNAs and clinical pathoparameters was analyzed using Spearman correlation analysis or canonical correlation analysis. The receiver-operator characteristic (ROC) curves were also generated to determine the specificity and sensitivity of each individual miRNA in distinguishing patients with CHB from Ctrls.
resultsmiRNA profile analysis showed that 34 miRNAs were differentially expressed between CHB and Ctrl subjects, in which 12 were up-regulated and 22 down-regulated in CHB subject (fold change > 2.0 and P < 0.01). The median levels of miR-122, -572, -575 and -638 were significantly higher (P < 1.00 × 10(-5)) while miR-744 significantly lower (P < 1.00 × 10(-6)) in CHB compared with the Ctrl. The levels of miR-122, -572 and -638 were also higher (P < 1.00 × 10(-3)) while the level of miR-744 lower in CHB (P < 0.05) than in NASH, although the difference between them was not as significant as that between CHB and Ctrl. ROC curve analysis revealed that the levels of miR-122, -572, -575, -638 and -744 in serum were sensitive and specific enough to distinguish CHB, NASH and Ctrl. Multivariate analysis further showed that the levels of these miRNAs were correlated with the liver function parameters. Most significantly, it was the scatter plot of principal component with the levels of these miRNAs, but not the parameters of liver function, which clearly distinguished CHB, NASH and Ctrl subjects.
conclusionSerum levels of miR-122, -572, -575, -638 and -744 are deregulated in patients with CHB or NASH. The levels of these miRNAs may serve as potential biomarkers for liver injury caused by CHB and NASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.